CRI-CCTG-0003/IND.240 an immunotherapy platform study in platinum-resistant high grade serous ovarian cancer (IPROC): Sub-studies A and B: Durvalumab (D) + mecbotamab vedotin (BA3011) or ozuriftamab vedotin (BA3021)
Helen J. MacKay, Anna V. Tinker, Brad H. Nelson, Dmitriy Zamarin et autres
1 citationCancer Treatment and Research Communications